Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on June 27, 2018. The report discloses a corporate governance event regarding the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Board Service Fee: $50,000 (prorated for 2018 service).
- Stock Options Granted: 10,213 shares.
- Exercise Price: $58.15 per share.
- Vesting Period: Four years.
Material Changes
The material change reported is the appointment of Dr. Carrolee Barlow, M.D., Ph.D. as a member of the Board of Directors effective June 27, 2018. No other material changes to operations or financial status are reported in this document.
Guidance, Outlook, and Risks
This filing contains no management guidance, financial outlook, risk factors, or discussion of contingencies. It strictly reports the appointment and associated compensatory arrangements. The filing notes that Dr. Barlow has not been appointed to any specific committees at this time.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 10,213 options granted.
- Confirm Dr. Barlow's specific qualifications and prior experience relevant to the pharmaceutical sector.
- Review the Company's 2012 Equity Incentive Plan to understand the terms of the option grant.
- Check subsequent filings for Dr. Barlow's assignment to specific board committees.